An integrative model of neuropsychiatric symptoms (NPS) in Alzheimer’s disease (AD) is lacking.
Objective:
In this study, we investigated the risk factors, anatomy, biology, and outcomes of NPS in AD.
Methods:
181 subjects were included from the Alzheimer’s Disease Neuroimaging Study (ADNI). NPS were assessed with the Neuropsychiatric Inventory Questionnaire at baseline and 6 months. NPI >3 was used as a threshold for NPS positivity. Three NPS courses were characterized: 1) minimal/absent (negative at 0 and 6 months, n = 77); 2) fluctuating (positive only at one time point, n = 53); 3) persistent (positive at both time points, n = 51). We examined the association between NPS course and family history of dementia, personal history of psychiatric disorders, cerebrospinal fluid biomarkers, atrophy patterns, as well as longitudinal cognitive and functional measures at 12 and 24 months (MMSE, CDR-SOB, FAQ).
Results:
AD subjects with absent, fluctuating, or persistent NPS had similar CSF amyloid-β and tau levels. AD subjects with minimal/absent NPS had less personal history of psychiatric disorders (35%) than those with fluctuating (57%; p = 0.015) or persistent NPS (47%, not significant). At 24 months, AD subjects with persistent NPS had worse cognitive (MMSE; p = 0.05) and functional (CDR-SOB; p = 0.016) outcomes. Dorsolateral prefrontal atrophy was seen in persistent NPS, but not in fluctuating NPS.
Conclusions:
Our results suggest that individuals with personal history of psychiatric disorders might be more vulnerable to develop NPS throughout the course of AD. The worst cognitive and functional outcomes associated with NPS in AD underscores the importance of monitoring NPS early in the disease course.
DickersonBC, WolkDA (2011) Dysexecutive versus amnesic phenotypes of very mild Alzheimer’s disease are associated with distinct clinical, genetic and cortical thinning characteristics. J Neurol Neurosurg Psychiatry82, 45–51.
RopackiSA, JesteDV (2005) Epidemiology of and risk factors for psychosis of Alzheimer’s disease: A review of 55 studies published from 1990 to 2003. Am J Psychiatry162, 2022–2030.
6.
BruenPD, McGeownWJ, ShanksMF, VenneriA (2008) Neuroanatomical correlates of neuropsychiatric symptoms in Alzheimer’s disease. Brain131, 2455–2463.
7.
RosenbergPB, NowrangiMA, LyketsosCG (2015) Neuropsychiatric symptoms in Alzheimer’s disease: What might be associated brain circuits?Mol Aspects Med43–44, 25–37.
8.
LopezOL, WisniewskiSR, BeckerJT, BollerF, DeKoskyST (1999) Psychiatric medication and abnormal behavior as predictors of progression in probable Alzheimer disease. Arch Neurol56, 1266–1272.
9.
RabinsPV, SchwartzS, BlackBS, CorcoranC, FauthE, MielkeM, ChristensenJ, LyketsosC, TschanzJ (2013) Predictors of progression to severe Alzheimer’s disease in an incidence sample. Alzheimers Dement9, 204–207.
10.
PetersME, SchwartzS, HanD, RabinsPV, SteinbergM, TschanzJT, LyketsosCG (2015) Neuropsychiatric symptoms as predictors of progression to severe Alzheimer’s dementia and death: The Cache County Dementia Progression Study. Am J Psychiatry172, 460–465.
11.
EmanuelJE, LopezOL, HouckPR, BeckerJT, WeamerEA, Demichele-SweetMA, KullerL, SweetRA (2011) Trajectory of cognitive decline as a predictor of psychosis in early Alzheimer disease in the cardiovascular health study. Am J Geriatr Psychiatry19, 160–168.
12.
IsmailZ, SmithEE, GedaY, SultzerD, BrodatyH, SmithG, Aguera-OrtizL, SweetR, MillerD, LyketsosCG, Neuropsychiatric Symptoms Professional Interest ISTAART, Area (2016) Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement12, 195–202.
13.
FolsteinMF, FolsteinSE, McHughPR (1975) “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
14.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
15.
McKhannG, DrachmanD, FolsteinM, KatzmanR, PriceD, StadlanEM (1984) Clinical diagnosis of Alzheimer’s disease Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology34, 939–944.
16.
KauferDI, CummingsJL, KetchelP, SmithV, MacMillanA, ShelleyT, LopezOL, DeKoskyST (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci12, 233–239.
17.
SchneiderLS, TariotPN, LyketsosCG, DagermanKS, DavisKL, DavisS, HsiaoJK, JesteDV, KatzIR, OlinJT, PollockBG, RabinsPV, RosenheckRA, SmallGW, LebowitzB, LiebermanJA (2001) National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry9, 346–360.
18.
SteinbergM, TschanzJT, CorcoranC, SteffensDC, NortonMC, LyketsosCG, BreitnerJC (2004) The persistence of neuropsychiatric symptoms in dementia: The Cache County Study. Int J Geriatr Psychiatry19, 19–26.
19.
LevyML, CummingsJL, FairbanksLA, BraviD, CalvaniM, CartaA (1996) Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer’s disease. Am J Psychiatry153, 1438–1443.
20.
DevanandDP, JacobsDM, TangMX, Del Castillo-CastanedaC, SanoM, MarderK, BellK, BylsmaFW, BrandtJ, AlbertM, SternY (1997) The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry54, 257–263.
21.
HauptM, KurzA, JannerM (2000) A 2-year follow-up of behavioural and psychological symptoms in Alzheimer’s disease. Dement Geriatr Cogn Disord11, 147–152.
22.
DugganC, ShamP, MinneC, LeeA, MurrayR (1998) Family history as a predictor of poor long-term outcome in depression. Br J Psychiatry173, 527–530.
23.
NormanRM, ManchandaR, MallaAK, HarricharanR, NorthcottS (2007) The significance of family history in first-episode schizophrenia spectrum disorder. J Nerv Ment Dis195, 846–852.
24.
FischlB, SalatDH, BusaE, AlbertM, DieterichM, HaselgroveC, van der KouweA, KillianyR, KennedyD, KlavenessS, MontilloA, MakrisN, RosenB, DaleAM (2002) Whole brain segmentation: Automated labeling of neuroanatomical structures in the human brain. Neuron33, 341–355.
25.
FischlB (2012) FreeSurfer. Neuroimage62, 774–781.
26.
ButtZA, StraussME (2001) Relationship of family and personal history to the occurrence of depression in persons with Alzheimer’s disease. Am J Geriatr Psychiatry9, 249–254.
27.
GreenRC, CupplesLA, KurzA, AuerbachS, GoR, SadovnickD, DuaraR, KukullWA, ChuiH, EdekiT (2003) Depression as a risk factor for Alzheimer disease: The MIRAGE Study. Arch Neurol60, 753–759.
28.
KrambergerMG, JelicV, KåreholtI, EnacheD, Eriksdotter JönhagenM, WinbladB, AarslandD (2012) Cerebrospinal fluid Alzheimer markers in depressed elderly subjects with and without Alzheimer’s disease. Dement Geriatr Cogn Dis Extra2, 48–56.
29.
TaylorWD, SteffensDC, MacFallJR, McQuoidDR, PayneME, ProvenzaleJM, KrishnanKRR (2003) White matter hyperintensity progression and late-life depression outcomes. Arch Gen Psychiatry60, 1090–1096.
30.
FrodlTS, KoutsoulerisN, BottlenderR, BornC, JägerM, ScupinI, ReiserM, MöllerH-J, MeisenzahlEM (2008) Depression-related variation in brain morphology over 3 years: Effects of stress?Arch Gen Psychiatry65, 1156–1165.
31.
TrzepaczPT, YuP, BhamidipatiPK, WillisB, ForresterT, TabasL, SchwarzAJ, SaykinAJ, InitiativeAsDN (2013) Frontolimbic atrophy is associated with agitation and aggression in mild cognitive impairment and Alzheimer’s disease. Alzheimers Dement9, S95–S104. e101.
32.
OudegaML, van ExelE, WattjesMP, ComijsHC, ScheltensP, BarkhofF, EikelenboomP, de CraenA, BeekmanA, StekML (2011) White matter hyperintensities, medial temporal lobe atrophy, cortical atrophy, and response to electroconvulsive therapy in severely depressed elderly patients. J Clin Psychiatry72, 104–112.
33.
BaldwinR, JeffriesS, JacksonA, SutcliffeC, ThackerN, ScottM, BurnsA (2004) Treatment response in late-onset depression: Relationship to neuropsychological, neuroradiological and vascular risk factors. Psychol Med34, 125–136.
34.
SalvadoreG, NugentAC, LemaitreH, LuckenbaughDA, TinsleyR, CannonDM, NeumeisterA, ZarateCA, DrevetsWC (2011) Prefrontal cortical abnormalities in currently depressed versus currently remitted patients with major depressive disorder. Neuroimage54, 2643–2651.
35.
MattssonN, SchottJM, HardyJ, TurnerMR, ZetterbergH (2016) Selective vulnerability in neurodegeneration: Insights from clinical variants of Alzheimer’s disease. J Neurol Neurosurg Psychiatry87, 1000–1004.
36.
DeMichele-SweetMA, SweetRA (2014) Genetics of psychosis in Alzheimer disease. Curr Genet Med Rep2, 30–38.
37.
ShahC, DeMichele-SweetMA, SweetRA (2017) Genetics of psychosis of Alzheimer disease. Am J Med Genet B Neuropsychiatr Genet174, 27–35.
38.
SweetRA, PollockBG, SukonickDL, MulsantBH, RosenJ, KlunkWE, KastangoKB, DeKoskyST, FerrellRE (2001) The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease. Int Psychogeriatr13, 401–409.
39.
de LeonMJ, McRaeT, TsaiJR, GeorgeAE, MarcusDL, FreedmanM, WolfAP, McEwenB (1988) Abnormal cortisol response in Alzheimer’s disease linked to hippocampal atrophy. Lancet2, 391–392.
SapolskyRM (2000) Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry57, 925–935.
42.
CaseyDE (2005) Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am J Med118, 15–22.
43.
AlexopoulosGS (2006) The vascular depression hypothesis: 10 years later. Biol Psychiatry60, 1304–1305.
44.
FannJ, LeonettiA, JaffeK, KatonW, CummingsP, ThompsonR (2002) Psychiatric illness and subsequent traumatic brain injury: A case control study. J Neurol Neurosurg Psychiatry72, 615–620.
45.
BarnesDE, YaffeK, ByersAL, McCormickM, SchaeferC, WhitmerRA (2012) Midlife vs late-life depressive symptoms and risk of dementia: Differential effects for Alzheimer disease and vascular dementia. Arch Gen Psychiatry69, 493–498.
46.
LuchsingerJA, HonigLS, TangMX, DevanandDP (2008) Depressive symptoms, vascular risk factors, and Alzheimer’s disease. Int J Geriatr Psychiatry23, 922–928.
47.
ChenST, SultzerDL, HinkinCH, MahlerME, CummingsJL (1998) Executive dysfunction in Alzheimer’s disease: Association with neuropsychiatric symptoms and functional impairment. J Neuropsychiatry Clin Neurosci10, 426–432.
48.
CummingsJL (1993) Frontal-subcortical circuits and human behavior. Arch Neurol50, 873–880.
49.
TekinS, MegaMS, MastermanDM, ChowT, GarakianJ, VintersHV, CummingsJL (2001) Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol49, 355–361.
50.
ZubenkoGS, MoossyJ, MartinezAJ, RaoG, ClaassenD, RosenJ, KoppU (1991) Neuropathologic and neurochemical correlates of psychosis in primary dementia. Arch Neurol48, 619–624.
51.
BoublayN, SchottAM, Krolak-SalmonP (2016) Neuroimaging correlates of neuropsychiatric symptoms in Alzheimer’s disease: A review of 20 years of research. Eur J Neurol23, 1500–1509.
CraigAD (2009) How do you feel—now? The anterior insula and human awareness. Nat Rev Neurosci10, 59–70.
56.
PorsteinssonAP, DryeLT, PollockBG, DevanandDP, FrangakisC, IsmailZ, MaranoC, MeinertCL, MintzerJE, MunroCA, PeltonG, RabinsPV, RosenbergPB, SchneiderLS, ShadeDM, WeintraubD, YesavageJ, LyketsosCG, CitADRG (2014) Effect of citalopram on agitation in Alzheimer disease: The CitAD randomized clinical trial. JAMA311, 682–691.
57.
SteinbergM, LyketsosCG (2012) Atypical antipsychotic use in patients with dementia: Managing safety concerns. Am J Psychiatry169, 900–906.
58.
TakadaM, FujimotoM, HosomiK (2016) Association between benzodiazepine use and dementia: Data mining of different medical databases. Int J Med Sci13, 825–834.
